The phase III drug study of Psoriasis in BMS met the standard

Bristol Myers Squibb's tyrosine kinase 2 (TYK2) inhibitor deucravacitinib outperformed Amed's Otzla in phase III psoriasis studies.


POETYK PSO-1
evaluated
deucravacitinib
as a treatment for patients with moderate to severe plaque-like psoriasis.The drug met both the common primary endpoint indicator and the placebo target, with more patients reaching the psoriasis area and severity index (
PASI
)
75 -
defined as
PASI
improving by at least
75
%.In addition, after 16
weeks of treatment with
Deucravacitinib

, the physician's static global assessment (
sPGA
) was rated clear or almost clear (
sPGA 0/1
).Baxalme's medicine also encountered a number of secondary endpoints, including a
PASI 75
response in week
16
and a
sPGA 0/1
patient ratio that showed better than Aming's
Otezla
.POETYK PSO-1
is the first of two global
III
studies to assess the safety and effectiveness of
deucravacitinib
in patients with moderate to severe plaque-like psoriasis compared to placebo and
Otezla
.Data from the second study
POETYK PSO-2
is expected to be released in the first quarter of
2021
and

in a wide range of immunomediable diseases."We are encouraged by the efficacy and safety observed in the
POETYK PSO-1
study, which supports us to see our new oral
TYK2
inhibitor
deucravacitinib
has the potential to be an important new treatment for psoriasis," said
Hirawat
Samit, Executive Vice President, Global Drug Development, BMS
.
”He added: "We recognise that new treatment options are urgently needed for people with immuno-mediated diseases such as psoriasis and are committed to developing potential new drugs that will give doctors more options to effectively treat and manage patients." (
cyy123.com
)original source: